Cytoreductive Nephrectomy in Metastatic Patients with Signs or Symptoms: Implications for Renal Cell Carcinoma Guidelines

Alessandro Larcher, Giuseppe Fallara, Giuseppe Rosiello, Chiara Re, Gianfranco Baiamonte, Stefano Agnesi, Daniele Cignoli, Gianmarco Colandrea, Giuseppe Basile, Alberto Briganti, Andrea Salonia, Roberto Bertini, Francesco Montorsi, Umberto Capitanio

Research output: Contribution to journalArticlepeer-review

Abstract

In conclusion, symptomatic presentation of metastatic renal cell carcinoma (mRCC) at diagnosis is more common than its asymptomatic presentation: two out of three patients suffer from any sign or symptom, and one out of three patients suffers from local signs or symptoms only. The study supports clinical decision making with the evidence that indication for cytoreductive nephrectomy has a positive impact on symptomatic status and that such beneficial response is maximal in patients with local signs and symptoms only. Further research and specific recommendations for symptomatic mRCC cases are required in the context of guideline-based management.

Original languageEnglish
Pages (from-to)321-326
Number of pages6
JournalEuropean Urology
Volume78
Issue number3
DOIs
Publication statusPublished - Sep 2020

Keywords

  • Cytoreductive nephrectomy
  • Guidelines
  • Kidney cancer
  • Metastasis
  • Symptoms
  • Systemic therapy

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Cytoreductive Nephrectomy in Metastatic Patients with Signs or Symptoms: Implications for Renal Cell Carcinoma Guidelines'. Together they form a unique fingerprint.

Cite this